Bioharmony Therapeutics is an early-stage biopharmaceutical company based in New York City, developing bacteriophage lysins for the treatment of multidrug-resistant (MDR) bacterial infections. Phage lysins are a new class of antimicrobials with a novel mechanism of action. Through phage-bacterial evolutionary selection, lysins target a critical component in the bacterial cell wall making resistance to them orders of magnitude less likely than conventional antibiotics. Such properties make lysins uniquely suitable for the treatment of MDR pathogens such as Acinetobacter baumannii (AB). The lead lysin candidate (BH01) is being developed as a locally delivered, nebulized drug for the treatment of AB infections in the pneumonia patients. Additional lysins target MDR Gram-negative bacterial infections.